Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Research in the area of cancer vaccines reported from Kyushu University
October 22nd, 2008
"We previously showed that a combination therapy with tumor cell-pulsed monocyte-derived dendritic cells (DCs) and activated lymphocytes was well tolerated in patients with disseminated carcinomas. Recently, accumulating evidence has indicated that regulatory T-cells (Tregs), a unique population of CD4(+) T-cells, are increased in patients with several advanced malignancies and prevent cell-mediated immune responses against tumors," scientists in Fukuoka, Japan report. "However, reports analyzing the relationship between the Tregs population and the effects of immunotherapy are extremely rare. In the present study, 22 patients received an intravenous injection of...
Source: Vaccine Weekly (2008-10-22)
|
